RESOURCES FROM THEWELL BIOSCIENCE

LYMPHOMOIDS: A TISSUE-BASED EX VIVO CULTURE SYSTEM FOR LYMPHOMA THERAPY SCREENING

VitroGel® RGD played a key role in preserving tumor architecture for effective drug testing in lymphoma research 

TheWell Bioscience recently published a research highlight from Nature Communications, highlighting a publication by Santamaria-Martínez et al., titled ‘Development of patient-derived lymphomoids with preserved tumor architecture for lymphoma therapy screening’.

In this study, VitroGel® RGD played a pivotal role in developing a novel platform for culturing lymphoma tissue fragments, known as lymphomoids. The researchers aimed to maintain the viability, proliferation, and structural integrity of lymphoma tissues ex vivo, which is crucial for accurate drug testing. 

Click to read the article, or watch the webinar presented by Dr. Albert Santamaria-Martínez,  the Cancer Researcher from EFPL to explore more. 

*All products listed on this site and sold through LAB-A-PORTER Limited are for research use only (RUO). Not for human use. Not for therapeutic or diagnostic use.